Abstract
Several recent randomized controlled trials offer firm evidence supporting the efficacy and safety of real-time continuous glucose monitoring (RT-CGM) in type 1 diabetes mellitus (T1DM). Improved metabolic control with significant lowering of glycated hemoglobin (A1C) along with other parameters of glycemia, and without a concomitant increase in hypoglycemia, has been demonstrated. However, poor compliance in adolescents has been a limiting factor in that age group. The potential of RT-CGM of reducing hypoglycemia in well-controlled individuals with T1DM is anticipated but remains to be confirmed. The current high cost of this technology may limit clinical experience in routine clinical settings.
| Original language | English |
|---|---|
| Pages (from-to) | 401-404 |
| Number of pages | 4 |
| Journal | Pediatric Endocrinology Reviews |
| Volume | 7 Suppl 3 |
| State | Published - Aug 2010 |
